Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

被引：0
|
作者：
Cho, B. C. [1 ]
Cheng, Y. [2 ]
Zhou, C. [3 ]
Ohe, Y. [4 ]
Imamura, F. [5 ]
Lin, M-C. [6 ]
Majem, M. [7 ]
Shah, R. [8 ]
Rukazenkov, Y. [9 ]
Todd, A. [10 ]
Markovets, A. [11 ]
Barrett, C. [11 ]
Chmielecki, J. [11 ]
Gray, J. E. [12 ]
Ramalingam, S. S. [13 ]
机构：
[1] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Div Med Oncol,Dept Internal Med, Seoul, South Korea
[2] Jilin Prov Canc Hosp, Dept Oncol, Changchun, Jilin, Peoples R China
[3] Tongji Univ, Pulm Hosp, Dept Oncol, Shanghai, Peoples R China
[4] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[5] Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan
[6] Kaohsiung Chang Gung Mem Hosp, Div Pulm & Crit Care Med, Kaohsiung, Taiwan
[7] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[8] Maidstone & Tunbridge Wells NHS Trust, Maidstone Hosp, Kent Oncol Ctr, Maidstone, Kent, England
[9] AstraZeneca, GMED Oncol, Global Med Dev, Cambridge, England
[10] AstraZeneca, Biometr & Informat Sci, Cambridge, England
[11] AstraZeneca, IMED Biotech Unit, Translat Sci, Waltham, ME USA
[12] H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL USA
[13] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA8
引用
收藏
页码：177 / 177
页数：1
相关论文
共 50 条
  • [1] Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
    Ramalingam, S. S.
    Cheng, Y.
    Zhou, C.
    Ohe, Y.
    Imamura, F.
    Cho, B. C.
    Lin, M-C.
    Majem, M.
    Shah, R.
    Rukazenkov, Y.
    Todd, A.
    Markovets, A.
    Barrett, J. C.
    Chmielecki, J.
    Gray, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study
    Bischoff, H.
    Bohnet, S.
    Reinmuth, N.
    Rueckert, A.
    zum Buschenfelde, Meyer C.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 132 - 133
  • [3] Acquired mechanisms of resistance to first-line (1L) osimertinib with or without platinum-based chemotherapy (CT) in EGFR-mutated (EGFRm) advanced NSCLC: Preliminary data from FLAURA2
    Lee, C. K.
    Robichaux, J. P.
    Janne, P. A.
    Kim, S-W.
    Kim, T. M.
    Kobayashi, K.
    Planchard, D.
    Sugawara, S.
    Yanagitani, N.
    Yang, T-Y.
    Markovets, A.
    Bhetaryia, P.
    Poole, L.
    Rukazenkov, Y.
    Hartmaier, R. J.
    Yang, J. C-H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1669 - S1670
  • [4] Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers-Applications and Limitations
    Ohara, Shuta
    Suda, Kenichi
    Mitsudomi, Tetsuya
    CELLS, 2021, 10 (02) : 1 - 14
  • [5] Complete evaluation of resistance mechanisms to first-line osimertinib requires tissue biopsy.
    Piotrowska, Zofia
    Piper-Vallillo, Andrew
    Banwait, Mandeep
    Hung, Yin P.
    Rao, Revati
    Muzikansky, Alona
    Meador, Catherine Belle
    Hata, Aaron N.
    Sequist, Lecia V.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers
    Choudhury, Noura J.
    Marra, Antonio
    Sui, Jane S. Y.
    Flynn, Jessica
    Yang, Soo-Ryum
    Falcon, Christina J.
    Selenica, Pier
    Schoenfeld, Adam J.
    Rekhtman, Natasha
    Gomez, Daniel
    Berger, Michael F.
    Ladanyi, Marc
    Arcila, Maria
    Rudin, Charles M.
    Riely, Gregory J.
    Kris, Mark G.
    Heller, Glenn
    Reis-Filho, Jorge S.
    Yu, Helena A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : 463 - 475
  • [7] Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study
    Besse, B.
    Lee, S-H.
    Lu, S.
    Stroyakovskiy, D.
    Yazici, O.
    Rodriguez Cid, J. R.
    Hayashi, H.
    Nguyen, D.
    Yang, J. C-H.
    Gottfried, M.
    Gelatti, A. C.
    Owen, S.
    Ou, S-H. I.
    Ennis, M.
    Sethi, S.
    Bauml, J. M.
    Zhang, J.
    Curtin, J. C.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2024, 35 : 1245 - 1246
  • [8] INSIGHT 2: a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance
    Smit, Egbert F.
    Dooms, Christophe
    Raskin, Jo
    Nadal, Ernest
    Tho, Lye M.
    Le, Xiuning
    Mazieres, Julien
    Hin, How S.
    Morise, Masahire
    Zhu, Viola W.
    Tan, Daniel
    Holmberg, Kristina H.
    Ellers-Lenz, Barbara
    Adrian, Svenja
    Brutlach, Sabine
    Schumacher, Karl M.
    Karachaliou, Niki
    Wu, Yi-Long
    FUTURE ONCOLOGY, 2022, 18 (09) : 1039 - 1054
  • [9] Identification of pretreatment genomic biomarkers and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers.
    Choudhury, Noura J.
    Marra, Antonio
    Yang, Soo-Ryum
    Falcon, Christina J.
    Heller, Glenn
    Kris, Mark G.
    Reis-Filho, Jorge S.
    Riely, Gregory J.
    Yu, Helena Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
    Chmielecki, Juliann
    Gray, Jhanelle E.
    Cheng, Ying
    Ohe, Yuichiro
    Imamura, Fumio
    Cho, Byoung Chul
    Lin, Meng-Chih
    Majem, Margarita
    Shah, Riyaz
    Rukazenkov, Yuri
    Todd, Alexander
    Markovets, Aleksandra
    Barrett, J. Carl
    Hartmaier, Ryan J.
    Ramalingam, Suresh S.
    NATURE COMMUNICATIONS, 2023, 14 (01)
12345